Sponsor Study ID:
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Adult and Children
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This study will have two parts. The drugs used in Part A are a targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are referred to as A+AVD. Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the drug combination reduces the number of patients who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening.
Part B will use brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called AN+AD. Participants will be given these drugs for up to 12 doses (up to 6 months). This part of the trial will look at whether this combination of drugs is safe and effective for treatment of cHL.
If you would like to contact a MUSC study team member to learn more information about this study, click